press release
Biosynex Press Release
Biosynex announces the extension of the tender offer period for the acquisition of Chembio Diagnostics, Inc. shares until April 26, 2023.
français3 pages
Chargement…
Chargement…
Manufacturer of rapid diagnostic tests and medical devices based in Illkirch-Graffenstaden, France, since 2005.
FranceFondée en 2005Fabricant · SantéISO 13485ISO 9001CE Marking
press release
Biosynex announces the extension of the tender offer period for the acquisition of Chembio Diagnostics, Inc. shares until April 26, 2023.
press release
BIOSYNEX announces a delay in the publication of its 2025 annual accounts and financial report, now rescheduled for April 30, 2026, due to ongoing safeguard proceedings.
press release
BIOSYNEX announces that the Strasbourg Judicial Court has extended the observation period of its safeguard procedure by 6 months, until September 28, 2026. The company continues to meet its operating debt obligations while implementing cost-reduction and reorganization measures to focus on profitable activities.
press release
BIOSYNEX announces the appointment of Nathalie Roos as an independent member of its Board of Directors to strengthen corporate governance and strategic development.
press release
Biosynex subsidiary Chembio Diagnostic Systems has received a $1.8 million grant from CARB-X to develop a rapid point-of-care diagnostic test for typhoid fever using the proprietary DPP technology platform.
press release
Biosynex subsidiary Chembio Diagnostic Systems has submitted the DPP Syphilis TnT test to the FDA for 510(k) clearance and CLIA waiver. The test, which received Breakthrough Device designation in July 2025, is designed to distinguish between active and treated syphilis in approximately 15 minutes using the DPP Micro Reader II.
press release
Biosynex 2025 annual revenue report showing 95.1 million Euro turnover, a 6 percent decrease compared to 2024. The document outlines the ongoing safeguard procedure initiated in September 2025, strategic restructuring efforts, and 2026 growth outlook focusing on high-value diagnostic and pharmacy product lines.
brochure
A brochure for the VitaPCR molecular diagnostic system, highlighting its ease of use, rapid 20-minute results, and suitability for point-of-care testing in emergency departments and laboratories.
brochure
Product brochure for the BIOSYNEX AMPLIFLASH molecular biology system, detailing the isothermal amplification technology for SARS-CoV-2 and GBS testing. Includes workflow descriptions, kit contents, and clinical utility for rapid diagnostic testing.
press release
Biosynex announces the launch of a capital increase with preferential subscription rights for shareholders, targeting 7.99 million euros to strengthen its balance sheet and secure cash flow.
press release
Official legal notice regarding a capital increase for BIOSYNEX, detailing shareholder rights, company structure, and share characteristics as published in the Bulletin des Annonces Légales Obligatoires.
press release
BIOSYNEX announces the successful completion of its capital increase with preferential subscription rights, raising 7.99 million euros gross. The operation resulted in the issuance of 7,987,161 new shares at 1.00 euro per share, with a subscription rate of 107%.
press release
BIOSYNEX SA 2025 annual results press release detailing a 5.9% revenue decline, restructuring efforts, and the ongoing safeguard procedure initiated in September 2025 to address financial difficulties and debt restructuring.
press release
BIOSYNEX announces its 2026 financial calendar, detailing the schedule for the publication of annual and quarterly revenue and results. The document also provides a corporate overview of the company's activities in rapid diagnostics, molecular biology, and biotherapy monitoring.
press release
Biosynex announces the resignation of independent director Brigitte Geny from the Board of Directors, effective January 19, 2026. The company also provides a brief overview of its business divisions and upcoming financial communications.
press release
BIOSYNEX subsidiary Chembio Diagnostic Systems has received a $0.5 million grant from the Gates Foundation to develop a rapid lateral flow diagnostic test for preeclampsia. The test detects sFlt-1 biomarkers in blood to assist in the clinical management of pregnant women, particularly in low- and middle-income countries.
press release
BIOSYNEX announces the opening of a safeguard procedure to restructure its liabilities and the liquidation of its subsidiary AVALUN, as ordered by the Strasbourg Judicial Court.
press release
BIOSYNEX announces the filing of a safeguard procedure for the parent company and a declaration of cessation of payments for its subsidiary AVALUN, following financial difficulties and a strategic review of its business units.
press release
Biosynex subsidiary Chembio Diagnostic Systems has been granted 'Breakthrough Device' status by the US FDA for its DPP Syphilis TnT test, a rapid point-of-care diagnostic tool designed to distinguish active syphilis from treated infections.
press release
BIOSYNEX reports a 6% decrease in revenue for the first half of 2025, totaling 50.8 million euros. The company highlights a strategic focus on higher-margin product lines, restructuring efforts, and upcoming product launches for the second half of 2025, alongside progress in US market regulatory approvals.
press release
Biosynex subsidiary Chembio Diagnostic Systems announces that the FDA has granted 'Breakthrough Device' status to the SURE CHECK HIV self-test, a rapid immunochromatographic test for home use.
press release
BIOSYNEX announces the successful completion of its capital increase with preferential subscription rights, raising 7.99 million euros gross. The operation resulted in the issuance of 7,987,161 new shares at 1.00 euro per share, with a subscription rate of 107%.
press release
BIOSYNEX 2024 financial results press release reporting 101.4 million Euro revenue, a 9 percent increase. The document details corporate restructuring, including site closures, debt renegotiation, and strategic focus on pharmacy and diagnostic divisions.
press release
BIOSYNEX announces its 2025 financial calendar, detailing the scheduled publication dates for annual revenue, annual results, and quarterly revenue reports.